Association of Single Nucleotide Polymorphism in MAOB and Risk of Levodopa-Induced Dyskinesias in Parkinson’s Disease
Objective: To identify genetic risk factors for developing levodopa-induced dyskinesias (LID) in patients with Parkinson’s disease (PD). Background: LID are common complications in PD, but…Identification of the optimal carbidopa concentration in subcutaneously administered ND0612
Objective: To identify the concentration of subcutaneous (SC) carbidopa (CD) that provides optimal bioavailability of a concomitant fixed concentration of levodopa (LD) when administered via…Combined Surgical Therapies for Optimal Management of Advanced Parkinson’s Disease
Objective: We report a case of a patient with advanced PD who began LCIG for refractory motor fluctuations while continuing longstanding STN-DBS. Background: LCIG and…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…Improvement in attention/memory domains in advanced Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel is associated with better quality of life
Objective: To evaluate the relationship between non-motor symptom (NMS) severity, quality of life (QoL), and activities of daily living (ADL) in advanced Parkinson’s disease (PD)…Effects of the administration of levodopa on postural control under visual tasks
Objective: We tested if the administration of levodopa leads the patients with Parkinson’s disease to sway significantly more than the controls, especially under challenging visual…Medication optimization in Parkinson’s disease patients with ON-state freezing using objective gait assessments
Objective: To determine whether objective gait assessments could guide therapeutic decision making in Parkinson’s disease (PD) patients reporting freezing of gait (FOG) in the levodopa-ON…Safety of levodopa-carbidopa intestinal gel treatment in advanced Parkinson’s disease patients receiving ≥ 2000 mg daily dose of levodopa
Objective: To examine the safety of levodopa-carbidopa intestinal gel treatment (LCIG, carbidopa-levodopa enteral suspension in the US) in advanced Parkinson’s disease (PD) patients that received…Off-Target Implications of Nurr1 Agonist Therapy in Parkinson’s disease
Objective: To examine the impact of Nurr1 agonists on regulation of striatal Nurr1 and levodopa (LD)-induced dyskinesias (LIDs) in a rat model of Parkinson’s disease…Factors associated with occurrence of motor complications among Parkinson’s disease patients with levodopa treatment in Estonia
Objective: To identify the factors associated with the occurrence of motor complications among patients with Parkinson’s disease (PD) who receive levodopa treatment. Background: Levodopa is the…
- « Previous Page
- 1
- …
- 51
- 52
- 53
- 54
- 55
- …
- 62
- Next Page »